SGI-1027: A Benchmark Quinoline-Based DNA Methyltransferase Inhibitor

Executive Summary: SGI-1027 is a potent, cell-permeable inhibitor of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, with IC₅₀ values of 6 μM, 8 μM, and 7.5 μM, respectively, in in vitro biochemical assays (Schwartz 2022). It achieves DNA methylation inhibition by competitively occupying the cofactor (Ado-Met) binding site, not the DNA substrate site (APExBIO). SGI-1027 induces DNMT1 degradation via the proteasomal pathway, amplifying its epigenetic effects. This leads to demethylation of CpG-rich promoter regions and reactivation of silenced tumor suppressor genes, such as P16 and TIMP3, in validated human cancer cell lines. SGI-1027, supplied by APExBIO, is widely used in studies of cancer epigenetics and therapeutic DNA methylation targeting (APExBIO).

Biological Rationale

DNA methylation is a reversible epigenetic modification catalyzed by DNA methyltransferases (DNMTs), primarily DNMT1, DNMT3A, and DNMT3B (Schwartz 2022). Aberrant hypermethylation of CpG islands in promoter regions of tumor suppressor genes (TSGs) is a hallmark of many cancers, leading to gene silencing and promoting oncogenesis. Pharmacological inhibition of DNMTs can restore TSG expression and alter cancer cell phenotypes. SGI-1027 specifically targets DNMTs, making it a valuable tool for cancer epigenetics research and preclinical therapeutic exploration.

Mechanism of Action of SGI-1027

SGI-1027 is a small molecule with the chemical name N-[4-[(2-amino-6-methylpyrimidin-4-yl)amino]phenyl]-4-(quinolin-4-ylamino)benzamide and a molecular weight of 461.52. Mechanistically, SGI-1027 acts as a competitive inhibitor at the S-adenosylmethionine (Ado-Met) cofactor binding site of DNMTs (APExBIO). It does not compete with the DNA substrate. This binding prevents methyl group transfer to DNA, resulting in inhibition of methylation activity in a dose-dependent manner. Crucially, SGI-1027 also promotes selective proteasomal degradation of DNMT1, further reducing methyltransferase activity and enhancing demethylation of CpG islands (Schwartz 2022).

Evidence & Benchmarks

• SGI-1027 inhibits DNMT1, DNMT3A, and DNMT3B with IC₅₀ values of 6 μM, 8 μM, and 7.5 μM, respectively, under standard in vitro conditions (25°C, pH 7.5) (Schwartz 2022).
• SGI-1027 competes with Ado-Met at the cofactor site, but not with the DNA substrate, as demonstrated by binding assays and enzyme kinetics (APExBIO).
• Treatment with SGI-1027 in RKO colon cancer cells leads to demethylation of P16 and TIMP3 promoter CpG islands and subsequent gene re-expression, verified via qRT-PCR and bisulfite sequencing (Schwartz 2022).
• SGI-1027 induces proteasomal degradation of DNMT1, confirmed by Western blot after MG132 (proteasome inhibitor) rescue experiments (Schwartz 2022).
• SGI-1027 is soluble in DMSO (≥22.25 mg/mL, 20–25°C, gentle warming) but is insoluble in water and ethanol. Solution stability is optimal at -20°C for short-term use (APExBIO).

This article extends the coverage in "SGI-1027: Advanced Mechanisms and Next-Generation Epigenetics" by providing explicit evidence benchmarks and practical workflow considerations for research use.

Applications, Limits & Misconceptions

SGI-1027 is primarily used in the following contexts:

• Epigenetic reactivation of tumor suppressor genes in cancer cell lines.
• Mechanistic studies on DNMT inhibition and DNA methylation dynamics.
• Preclinical evaluation of therapeutic DNA methylation targeting strategies (Schwartz 2022).
• Studies requiring selective DNMT1 degradation via the proteasomal pathway.

Compared to the evidence-based, scenario-driven guide in "SGI-1027 (SKU B1622): Practical Solutions for Reliable DNMT Inhibition", this article focuses on the molecular basis and benchmark data supporting these applications.

Common Pitfalls or Misconceptions

• SGI-1027 is not effective in demethylating all genomic loci: Efficacy is context-dependent and may vary with chromatin accessibility and cell type (Schwartz 2022).
• Not water- or ethanol-soluble: Use only DMSO as a solvent for stock solutions; precipitation or inactivity may occur with incompatible solvents (APExBIO).
• Does not directly bind DNA: Its inhibition is restricted to the cofactor (Ado-Met) site of DNMTs, so it will not work in systems lacking functional DNMTs.
• Not a pan-epigenetic modulator: SGI-1027 does not inhibit histone-modifying enzymes or other non-DNMT epigenetic regulators.
• Limited long-term solution stability: Solutions must be freshly prepared or kept at -20°C for short-term use; avoid repeated freeze-thaw cycles.

Workflow Integration & Parameters

SGI-1027 (SKU B1622) from APExBIO is provided as a solid and should be dissolved in DMSO at concentrations up to 22.25 mg/mL with gentle warming. Typical working concentrations in cell-based assays range from 1 μM to 10 μM, depending on the cell model and research objective. For stability, aliquot solutions and store at -20°C, minimizing freeze-thaw cycles. In vitro experiments should include vehicle (DMSO) controls to distinguish compound effects from solvent artifacts. For DNA methylation analysis, employ bisulfite sequencing or methylation-specific PCR post-treatment. DNMT1 degradation can be verified by Western blot analysis; use proteasome inhibitors (e.g., MG132) to confirm pathway specificity.

This workflow guidance expands on the practical compatibility strategies found in "SGI-1027 (SKU B1622): Practical Solutions for DNA Methylation Experiments" by specifying key handling and assay parameters.

Conclusion & Outlook

SGI-1027 is a well-characterized quinoline-based DNA methyltransferase inhibitor with robust, selective inhibition of DNMT1/3A/3B, potent CpG island demethylation, and documented reactivation of tumor suppressor genes in cancer models. Its unique mechanism—competitive Ado-Met binding and DNMT1 degradation—provides a research advantage in dissecting DNA methylation pathways. Supplied by APExBIO, SGI-1027 is an essential tool for advancing cancer epigenetics and exploring therapeutic demethylation strategies. For detailed product specifications and ordering information, visit the SGI-1027 product page.